Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Clarity Capital Partners LLC

Clarity Capital Partners LLC boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 21.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,142 shares of the medical research company’s stock after acquiring an additional 1,973 shares during the period. Clarity Capital Partners LLC’s holdings in Edwards Lifesciences were worth $825,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in EW. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth approximately $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the fourth quarter worth $30,000. Prospera Private Wealth LLC acquired a new position in Edwards Lifesciences in the third quarter worth $32,000. Avior Wealth Management LLC boosted its holdings in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the period. Finally, JFS Wealth Advisors LLC raised its holdings in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 6.9 %

Shares of NYSE:EW opened at $75.83 on Thursday. The stock has a market capitalization of $44.72 billion, a price-to-earnings ratio of 10.94, a PEG ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a 50 day moving average price of $72.47 and a 200 day moving average price of $69.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on EW shares. Robert W. Baird decreased their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Piper Sandler lifted their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday. Barclays increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, December 2nd. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $79.71.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.